You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雙成藥業(002693.SZ):注射用胸腺法新獲得巴基斯坦藥品註冊批件
格隆匯 01-03 18:20

格隆匯1月3日丨雙成藥業(002693.SZ)公佈,公司於近日收到巴基斯坦藥品監督管理局(Drug Regulatory Authority of Pakistan)核准簽發的注射用胸腺法新(基泰)註冊批件。

胸腺法新是由28個氨基酸組成的化學合成的多肽類免疫調節劑。注射用胸腺法新主要用於慢性乙型肝炎、腫瘤、老年科及感染類疾病等的治療及肌體免疫力提高,同時,該產品已通過國家藥品監督管理局注射劑仿製藥質量和療效一致性評價以及獲得意大利藥品管理局頒發的上市許可證。其適應症為:1)慢性乙型肝炎;2)作為免疫損害病者的疫苗免疫應答增強劑。免疫系統功能受到抑制者,包括接受慢性血液透析和老年病患者,本品可增強病者對病毒性疫苗,如流感疫苗或乙肝疫苗的免疫應答。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account